Active Ingredient History
Clazakizumab, an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Arthritis, Psoriatic (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 2)
Atherosclerosis (Phase 2/Phase 3)
Cachexia (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
COVID-19 (Phase 2/Phase 3)
Crohn Disease (Phase 2)
Fatigue (Phase 2)
Frailty (Phase 2)
Graft Rejection (Phase 3)
Graft vs Host Disease (Phase 1/Phase 2)
Inflammation (Phase 2)
Kidney Diseases (Phase 1/Phase 2)
Kidney Failure, Chronic (Phase 2/Phase 3)
Kidney Transplantation (Phase 1/Phase 2)
Organ Transplantation (Phase 1/Phase 2)
Stomatitis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue